Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 2
1971 1
1986 1
1995 1
1996 2
1997 1
1999 2
2000 1
2001 1
2003 1
2005 7
2006 5
2007 6
2008 8
2009 13
2010 10
2011 8
2012 6
2013 3
2014 3
2015 4
2016 8
2017 7
2018 7
2019 15
2020 14
2021 14
2022 23
2023 20
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Results by year

Filters applied: . Clear all
Page 1
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators. Ray-Coquard I, et al. Among authors: burges a. N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361. N Engl J Med. 2019. PMID: 31851799 Clinical Trial.
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
Ray-Coquard I, Leary A, Pignata S, Cropet C, González-Martín A, Marth C, Nagao S, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alia EM, Bogner G, Yoshida H, Lefeuvre-Plesse C, Buderath P, Mosconi AM, Lortholary A, Burges A, Medioni J, El-Balat A, Rodrigues M, Park-Simon TW, Dubot C, Denschlag D, You B, Pujade-Lauraine E, Harter P; PAOLA-1/ENGOT-ov25 investigators. Ray-Coquard I, et al. Among authors: burges a. Ann Oncol. 2023 Aug;34(8):681-692. doi: 10.1016/j.annonc.2023.05.005. Epub 2023 May 19. Ann Oncol. 2023. PMID: 37211045 Free article. Clinical Trial.
Strategy.
Trillsch F, Reichenbach J, Czogalla B, Kraus F, Burges A, Mahner S, Kessler M. Trillsch F, et al. Among authors: burges a. J Vis Exp. 2024 Feb 23;(204). doi: 10.3791/66467. J Vis Exp. 2024. PMID: 38465946
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms.
Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, Kim JW, Raspagliesi F, Lampe B, Aletti G, Meier W, Cibula D, Mustea A, Mahner S, Runnebaum IB, Schmalfeldt B, Burges A, Kimmig R, Scambia G, Greggi S, Hilpert F, Hasenburg A, Hillemanns P, Giorda G, von Leffern I, Schade-Brittinger C, Wagner U, du Bois A. Harter P, et al. Among authors: burges a. N Engl J Med. 2019 Feb 28;380(9):822-832. doi: 10.1056/NEJMoa1808424. N Engl J Med. 2019. PMID: 30811909 Free article. Clinical Trial.
Publisher Erratum: Langer Leidensweg bei Endometriose.
Beyer S, Trillsch F, Kost B, Burges A, Mahner S, Kolben T. Beyer S, et al. Among authors: burges a. MMW Fortschr Med. 2023 Feb;165(2):66. doi: 10.1007/s15006-023-2298-0. MMW Fortschr Med. 2023. PMID: 36703076 German. No abstract available.
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.
Pfisterer J, Joly F, Kristensen G, Rau J, Mahner S, Pautier P, El-Balat A, Kurtz JE, Canzler U, Sehouli J, Heubner ML, Hartkopf AD, Baumann K, Hasenburg A, Hanker LC, Belau A, Schmalfeldt B, Denschlag D, Park-Simon TW, Selle F, Jackisch C, Burges A, Lück HJ, Emons G, Meier W, Gropp-Meier M, Schröder W, de Gregorio N, Hilpert F, Harter P. Pfisterer J, et al. Among authors: burges a. J Clin Oncol. 2023 Feb 1;41(4):893-902. doi: 10.1200/JCO.22.01010. Epub 2022 Nov 4. J Clin Oncol. 2023. PMID: 36332161 Clinical Trial.
[Endometriosis - a seriously understimated disease].
Beyer S, Trillsch F, Kost B, Burges A, Mahner S, Kolben T. Beyer S, et al. Among authors: burges a. MMW Fortschr Med. 2022 Dec;164(21-22):64-66. doi: 10.1007/s15006-022-2175-2. MMW Fortschr Med. 2022. PMID: 36510075 Review. German. No abstract available.
Treatment and survival of patients with malignant ovarian sex cord-stromal cell tumours: An analysis of the Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) study group CORSETT database.
Klar M, Plett H, Harter P, Heitz F, Kommoss S, Hartkopf AD, Grube M, Roser E, Sehouli J, Braicu I, Czogalla B, Burges A, Bossart M, Hasanov MF, Link T, Staebler A, Mayr D, Buderath P, Hasenburg A. Klar M, et al. Among authors: burges a. J Surg Oncol. 2023 Jul;128(1):111-118. doi: 10.1002/jso.27248. Epub 2023 Mar 28. J Surg Oncol. 2023. PMID: 36975108 Review.
169 results